Ministry of AYUSH asks Patanjali to prove claim on Coronavirus medicine, ban on publicity
There is a lot of struggle going on in developing Coronavirus Medicine and Vaccine in India and abroad. Meanwhile, Baba Ramdev and Acharya Balakrishna have claimed to make Coronavirus medicine on behalf of their Patanjali Ayurveda. On Tuesday, Baba Ramdev has also announced this medicine called Coronil. Now Ayush ministry has asked Patanjali Ayurveda to take full information regarding this medicine and ask for complete information. The Ministry of AYUSH has said that it has no information regarding the claims of facts and scientific research regarding this drug.
Along with this, the Ministry of AYUSH has asked Patanjali Ayurved to stop advertising and promoting the claims of medicine. The Ministry of AYUSH has said that this ban will remain until the issue is duly investigated. The Ministry has requested the concerned State Licensing Authority of the Government of Uttarakhand to provide information on the licensing of Ayurvedic medicines and the permission related to the product claimed for treatment of COVID-19.
Patanjali Ayurved Limited has been asked by the Ministry to provide information as soon as possible on the name and composition of the drug being claimed to be able to treat COVID 19. In this, information has also been asked about the place and hospital where research and study were done. In addition, information on protocol, sample size, Institutional Ethics Committee clearance, CTRI registration, and result of studies (IES) has also been sought.
Let us know that Yoga Guru Swami Ramdev launched the coronavirus drug ‘Coronil’ on the market on Tuesday and claimed that this drug, made after intensive study and research of herbs from Ayurveda method, is benefiting 100 percent patients.
Baba Ramdev said that Patanjali is the first ayurvedic institute in the world that has launched the corona epidemic medicine certified after extensive study and research of herbs. He said that this medicine is benefiting 100 percent of patients. Simultaneously, controlled clinical trials were conducted on 100 patients, in which 69 percent of patients were cured within three days and 100 percent of patients were cured within four days and their test report was negative.
